Stocktoria
Novo Nordisk A/S NOVO-B.CO
Novo Nordisk A/S (NOVO-B.CO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 3.72% (safety: moderate). FY2025 revenue was kr 309.1B at a 33.1% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 36 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | -0.08 |
| Retained earnings / assets | 0.36 |
| EBIT / assets | 0.235 |
| Equity / liabilities | 0.556 |
FAQ
Is NOVO-B.CO financially healthy?
Novo Nordisk A/S's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does NOVO-B.CO pay a dividend, and is it safe?
Yes. Novo Nordisk A/S pays a dividend yielding about 3.72% with a 50.5% payout ratio, rated “moderate” for safety.
How profitable is NOVO-B.CO?
In FY2025, Novo Nordisk A/S had a net margin of 33.1% and a return on equity of 52.8%.
Source: company filings via Yahoo Finance · DK · as of 2025-12-31. Figures in DKK; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.